Clinical characteristics of study patients with B-CLL
| Variable . | All patients . | CD38+patients . | CD38− patients . | P . |
|---|---|---|---|---|
| No. patients (%) | 76 (100)† | 25 (36) | 45 (64) | — |
| Median age, y | 67 | 66 | 68 | .309* |
| Male sex (%) | 55 of 76 (72) | 19 of 25 (76) | 31 of 45 (69) | .528† |
| Disease stage | ||||
| Binet A (%) | 31 of 75 (41) | 4 of 25 (16) | 24 of 44 (55) | .002† |
| Binet B (%) | 21 of 75 (28) | 10 of 25 (40) | 10 of 44 (22) | — |
| Binet C (%) | 23 of 75 (31) | 11 of 25 (44) | 10 of 44 (22) | — |
| White blood cell count, ×10−3/μL N = 75 | 77.5 ± 77.7 | 41.0 ± 76.0 | 60.9 ± 82.6 | .210* |
| Hemoglobin level, g/dL; N = 69 | 12.8 ± 2.4 | 12.6 ± 2.6 | 13.6 ± 2.3 | .135* |
| Platelet count, ×10−3/μL; N = 68 | 154.0 ± 74.0 | 131.0 ± 59.0 | 161.5 ± 79.6 | .124* |
| Bone marrow histology, % infiltration; N = 44 | 54.9 ± 30.5 | 80.0 ± 25.9 | 35.0 ± 24.1 | .001* |
| Thymidine kinase, IU/L; N = 47 | 19.7 ± 27.2 | 19.9 ± 39.7 | 6.0 ± 10.0 | .002* |
| β2-microglobulin, mg/L; N = 64 | 3.00 ± 1.9 | 2.8 ± 2.3 | 1.9 ± 1.8 | .061* |
| Lactate dehydrogenase level, IU/L; N = 63 | 237.9 ± 67.7 | 254.0 ± 75.3 | 215.0 ± 55.0 | .020* |
| Variable . | All patients . | CD38+patients . | CD38− patients . | P . |
|---|---|---|---|---|
| No. patients (%) | 76 (100)† | 25 (36) | 45 (64) | — |
| Median age, y | 67 | 66 | 68 | .309* |
| Male sex (%) | 55 of 76 (72) | 19 of 25 (76) | 31 of 45 (69) | .528† |
| Disease stage | ||||
| Binet A (%) | 31 of 75 (41) | 4 of 25 (16) | 24 of 44 (55) | .002† |
| Binet B (%) | 21 of 75 (28) | 10 of 25 (40) | 10 of 44 (22) | — |
| Binet C (%) | 23 of 75 (31) | 11 of 25 (44) | 10 of 44 (22) | — |
| White blood cell count, ×10−3/μL N = 75 | 77.5 ± 77.7 | 41.0 ± 76.0 | 60.9 ± 82.6 | .210* |
| Hemoglobin level, g/dL; N = 69 | 12.8 ± 2.4 | 12.6 ± 2.6 | 13.6 ± 2.3 | .135* |
| Platelet count, ×10−3/μL; N = 68 | 154.0 ± 74.0 | 131.0 ± 59.0 | 161.5 ± 79.6 | .124* |
| Bone marrow histology, % infiltration; N = 44 | 54.9 ± 30.5 | 80.0 ± 25.9 | 35.0 ± 24.1 | .001* |
| Thymidine kinase, IU/L; N = 47 | 19.7 ± 27.2 | 19.9 ± 39.7 | 6.0 ± 10.0 | .002* |
| β2-microglobulin, mg/L; N = 64 | 3.00 ± 1.9 | 2.8 ± 2.3 | 1.9 ± 1.8 | .061* |
| Lactate dehydrogenase level, IU/L; N = 63 | 237.9 ± 67.7 | 254.0 ± 75.3 | 215.0 ± 55.0 | .020* |
A CLL population was considered CD38+ when more than 20% of the gated population (CD19+CD5+ cells) expressed the CD38 antigen.12 14
Calculated using Wilcoxon rank sum test; †calculated using χ2 test.
In 6 patients the CD38 expression status was not assessed.
Data are mean ± SD. Because of rounding, percentages do not always add up to 100. — indicates not applicable.